新型冠状病毒肺炎感染对免疫性血小板减少症患者的矛盾效应。
Paradoxical effect of SARS-CoV-2 infection in patients with immune thrombocytopenia.
作者信息
de la Cruz-Benito Beatriz, Rivas-Pollmar María I, Álvarez Román María T, Trelles-Martínez Roberto, Martín-Salces Monica, Lázaro-Del Campo Paula, Ramírez-López Andrés, García-Barcenilla Sara, Cebanu Tamara, Acuña-Butta Paula, Monzón-Manzano Elena, González-Zorrilla Elena, Jiménez-Yuste Victor, Butta Nora V
机构信息
Unit of Thrombosis and Hemostasis, Hematology Department, La Paz University Hospital - IdiPAZ, Madrid, Spain.
Autonoma University of Madrid, Madrid, Spain.
出版信息
Br J Haematol. 2021 Mar;192(6):973-977. doi: 10.1111/bjh.17077. Epub 2020 Sep 10.
Thrombocytopenia has been identified as a common complication of severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) infection in the general population. In an attempt to determine the impact of coronavirus disease 2019 (COVID-19) in patients with immune thrombocytopenia (ITP), a retrospective single-centre study was performed. Thrombocytosis was observed in patients with chronic ITP after SARS-CoV-2 infection, frequently needing treatment adjustment or even discontinuation of therapy. Relapses and newly diagnosed cases showed a fast response after initial treatment compared to ITP. Reduced immune activity due to lymphopenia during COVID-19 could explain this paradoxical effect, although further studies are needed.
血小板减少症已被确认为普通人群中严重急性呼吸综合征冠状病毒2（SARS-CoV-2）感染的常见并发症。为了确定2019年冠状病毒病（COVID-19）对免疫性血小板减少症（ITP）患者的影响，进行了一项回顾性单中心研究。在SARS-CoV-2感染后的慢性ITP患者中观察到了血小板增多症，这些患者经常需要调整治疗或甚至停止治疗。与ITP相比，复发和新诊断病例在初始治疗后显示出快速反应。尽管还需要进一步研究，但COVID-19期间淋巴细胞减少导致的免疫活性降低可能解释了这种矛盾的效应。
Zotero 插件